Dr. Asma Deeb is a Consultant and Chief of Pediatric Endocrinology at Mafraq Hospital, Abu Dhabi. She trained in the UK since 1991. Dr. Deeb obtained an MD degree in Growth Hormone Gene Expression in 2002 from University of Newcastle. She was appointed as a Clinical Lecturer in Pediatric Endocrinology at the University of Cambridge between 2001 and 2005 and obtained a CCST in Paediatric Endocrinology. Dr. Deeb has special interest in disorders of sexual differentiation, use of technology in management of children with diabetes and genetics of diabetes mellitus in which she has published in Peer Review Journals.
Dr Asma Binjab is a Canadian board certified pediatric Endocrinologist and Diabetologist, she has wide experience in managing various Endocrine disorders in children and adolescents like short stature, tall stature, thyroid problems, puberty disorders,adrenal insufficiency ,disorders of sexual differentiation, .etc. In the field of Diabetes, she treats all types of Diabetes in children and adolescents, also fully experienced in the use of advance technology (insulin pumps, continuous glucose monitoring sensor, etc.)In management of diabetes.
After medical school,she did a PhD on the use of pumps in newly onset pediatricdiabetes (1986, Prof Bruining) in Rotterdam , Netherlands,. Since then, her interest in diabetes technology has remained. She did her paediatric training in the Netherlands, Luxembourg and France (1993),followed in 1999 by paediatric endocrinology-diabetology. In 1988 she obtained a University DU in Public Health in Nancy , France and a GCPI in 1998 (UK)
After arrival in Luxembourg, she participated in the creation of the multidisciplinaryteam (DECCP) to improve care for children and adolescents with diabetes and endocrine pathologies. Current focus is quality of care control improvement in paediatric and adolescent diabetes through benchmarking and diabetes technology. Together with the integrated biobank (IBBL) and the Luxemburg Center for System Biomedicine (LCSB) research projects on the microbiome in relationship with diabetes are ongoing.
She received several research grants from the EU, interregional and international funding structures and is PI in Luxembourg for SPIDIMAN and INNODIA. She has published over 100papersin peer reviewed journalsand several chapters in paediatric books. Between 2012-2016 she served on the ISPAD Executive Board as Secretary General.
Dr. Celia Rodd is an Associate Professor in the Department of Pediatrics and Child Health at the University of Manitoba; she recently moved to Winnipeg after working for 20 years at the Montreal Children's Hospital, McGill University. At McGill University, she had the pleasure of being the Program Director for Pediatric Endocrinology for 15 years. She trained at the University of Toronto (BSc, MD, Clinical Endocrinology Fellowship), McGill University (Pediatrics Residency), the University of Minnesota (Research Endocrinology Fellowship) and at the London School of Hygiene and Tropical Medicine (Masters of Epidemiology). Celia's clinical and research interests focus on calcium homeostasis and bone physiology and their associated disorders. She is particularly interested in defining optimal vitamin D intake for healthy Canadian children and ensuring compliance with current guidelines. Celia has worked with the Canadian Pediatric Endocrine Group to develop optimized growth charts in Canada based on the 2006-2007 WHO growth charts. She has published over 80 peer-reviewed manuscripts in a wide spectrum of endocrine and diabetes related topics. Additionally, she has been funded by numerous agencies including Canadian Institute of Health Research.
David S. Cooper is currently Professor of Medicine at the Johns Hopkins University School of Medicine and Professor of International Health at the Bloomberg Johns Hopkins School of Public Health. He serves as an Editor-In-Chief for Endocrinology for Up-to-Date, as a Contributing Editor of the Journal of the American Medical Association (JAMA), and as the Deputy Editor of the Journal of Clinical Endocrinology and Metabolism. He is the Chair of the Subspecialty Board for Endocrinology, Diabetes, and Metabolism of the American Board of Internal Medicine. Dr. Cooper is the past President the American Thyroid Association, and the recipient of the American Thyroid Association Distinguished Service Award.
Dr.Ebaa Al-Ozairi (BMSc (hons), MBChB, MRCP (UK), CCT (UK), FACN) is an Assistant Professor at Kuwait University and a consultant Diabetes, Endocrine and Nutrition. Dr. Ebaa has completed her intercalated BMSc (hons) in molecular pathology at Dundee University (UK) and graduated from Aberdeen University (UK) for her medical undergraduate studies. Ebaa then joined Newcastle University (UK) for her specialist training in Diabetes and Endocrinology (CCT). During her postgraduate studies in UK, Ebaa was awarded The Fulbright Fellowship to Joslin Diabetes Centre, affiliated with Harvard Medical School, Boston, USA.
Her research interest includes diabetes education, technology, metabolic surgery and obesity. Ebaa has been accredited by the Royal College of Physician (UK) as a medical educator, and is an associate practitioner at the UK Higher Education National Academy having completed teaching Fellowship. Ebaa has completed her Fellowship in obesity and holds the American Board for Physician Nutrition Specialist and is a Fellow at the American College of Nutrition. She also directs DAFNE type 1 diabetes education program and currently is granted the training centre for the Middle East. Ebaa has completed her Rabkin Fellowship in medical Education at Harvard Medical School. Dr Al-Ozairi is on the editorial board for Austin Medical Journal and the Journal of Community Medicine and Public Health. She is also a reviewer for Diabetic Medicine, Obesity Surgery, and Practical International Diabetes. She has 3 chapters in International books and an author in Medscape, Bariatric Times and Endodiabology. Dr Al-Ozairi has won his highness the Amir Gold medal electronic award and the Arab regional award for founding sokary.org. In addition, she is the Treasurer of the American Association of Clinical Endocrinologist- Gulf Chapter.
Dr. Elham Mohamed Al Amiri is a prominent consultant pediatrician and a renowned academic in the UAE. Dr. Al Amiri received her medical degree from King Faisal University in Saudi Arabia in 1993, and then she obtained her Master's degree in Pediatrics from Trinity College at the University of Dublin (Ireland). She is currently an adjunct assistant professor at the college of medicine, University of Sharjah, and a consultant pediatrician at Al Qassimi Hospital in Sharjah, where she is also the head of the Diabetes and Endocrine Unit.
Throughout her career, Dr. Al Amiri had worked with numerous distinguished hospitals such as Al Ain Hospital, Latifa Hospital and Rashid Hospital before joining Al Qassimi Hospital in Sharjah. Additionally, she was a pediatric endocrinology fellow at King Faisal Specialist Hospital and Research center in Saudi Arabia and an ESPE Clinical fellow at the Royal Manchester Children's Hospital in the UK.
Consultant Endocrinologist & the Head of the Endocrine Department-Dubai Hospital.
Chairperson of Diabetes Combat and Control Committee - DHA
Member of National Diabetes Committee
General Secretary of EDS
Senior Lecturer at Dubai Medical College
Host examiner for MRCP, PACES exam.
Actively involved in various studies in diabetes and endocrinology with several publications.
Professor Francesco Giorgino, MD, PhD
University of Bari Aldo Moro, Bari, Italy
Francesco Giorgino is Professor of Endocrinology and Metabolism, Director of the Specialty School of Endocrinology and Metabolism, and Chairman of the Department of Emergency and Organ Transplantation at the Universityof Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinologyat the University Hospital PoliclinicoConsorziale. Professor Giorgino received his M.D. degree from the Universityof Bari Aldo Moro and his Ph.D. degree from the University of Naples Federico II, in Italy. After completing clinical and research training in endocrinology and metabolism at the University of Catania, Italy, he worked for several years at the Joslin Diabetes Center and Harvard Medical School in Boston, MA, USA, first as a postdoctoral research fellow and then as a visiting scientist.
Professor Giorgino has received distinguished scientific awards from various international and national institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), the Glaxo-Wellcome Award from the European Association for the Study of Diabetes (EASD), the Aldo Pinchera and Cassano Awards from the Italian Society of Endocrinology, and the Alcmeone Award from the Italian Society of Diabetology. He has been the Italian Delegate in various European Commission Cooperation in Science and Technology (COST)actions for diabetes research. Professor Giorgino has served on many national commissions and national boards, including the Executive Committee of the Italian Society of Diabetology, and the Scientific Committee of the Italian Society of Endocrinology.
He is or has been a member of the Editorial Boards for the following journals: PLoS ONE,Journal of Endocrinology, Endocrinology, Journal of Endocrinological Investigation, Adipocyte, ActaDiabetologica, Cardiorenal Medicine, and Diabetes Metabolism Research and Reviews. He has published more than 150 original and review articles in prestigious scientific journals and has been an invited speaker at many national and international meetings. Professor Giorgino's research interests include the mechanisms of insulin resistance and beta-cell dysfunction in type 2 diabetes mellitus, the pathophysiology of adipose tissue, and the pharmacological modulation of insulin action and beta-cell function.
Professor Rubino's research showed that the anti-diabetes effect of certain bariatric procedures, particularly gastric bypass surgery, results from mechanisms beyond weight loss. This evidence provided a scientific rationale for surgical treatment of type 2 diabetes, including that of less obese patients. Professor Rubino's research-finding and theories also point to a role of the gastrointestinal tract in the pathophysiology of diabetes and obesity. His clinical expertise includes laparoscopic, bariatric, metabolic and upper digestive surgery, including gastric bypass, sleeve gastrectomy, gastric banding and novel procedures. He is internationally recognized as one of the world's leaders in the research, teaching and practice of metabolic and weight-loss surgery.
Professor Rubino received his MD and completed his residency in general surgery at the Catholic University / Policlinico Gemelli in Rome, Italy. He completed fellowships in laparoscopic surgery at the European Institute of Telesurgery in Strasbourg, France; Mount Sinai Medical Center, New York; and Cleveland Clinic.
A member of many professional organizations, Professor Rubino is the recipient of numerous awards, has given hundreds of presentations throughout the world, and is the author of over 100 articles in peer-reviewed journals and book chapters. He was one of the co-organizers of the landmark Diabetes Surgery Summit in Rome in 2007, an influential scientific event where leading international authorities for the first time reached a consensus on the best candidates for the surgical treatment of diabetes. Professor Rubino also served as Congress Director and organized the 1st and 2nd World Congress on Interventional Therapies for Type 2 Diabetes in New York City, bringing together over 1,000 multidisciplinary diabetes experts from 62 countries.
For several consecutive years, Professor Rubino was selected by both US News & World Report and Castle Connolly as one of "America's Top Doctors" and was selected by Crain's NY Business as a notable "40 under 40", which recognizes young rising stars in the healthcare, business, non-profit and entertainment industries.
His work has been featured in journals such as the New York Times, the Wall Street Journal, Newsweek, 60 Minutes on CBS, the Guardian, and the New Scientists as well as on national TVs and newspapers in Japan, Italy, Qatar, Brazil, South Africa and other countries.
Dr Haidar Al Yousuf is the Director of Health Funding at the Dubai Health Authority. His role is the de-sign and implementation of the future Health care funding system for the Emirate of Dubai, as well as running Enaya, Government of Dubai employee Health insurance program and regulating the health insurance market. Dr Al Yousuf has been the DHA's Transition Director for phase three, assisting His Excellency the Director General in setting up the DHA's sector role as the authority in charge of the outcomes of the health sector in Dubai. Dr Al Yousuf is a specialist family physician (MRCGP), he is holds a medical degree (MBCHB) from Dundee University, UK where he also practiced and published a number of papers. He is a Graduate of the prestigious Mohammed bin Rashid Leadership development program. Prior to his role at the DHA, Dr Al Yousuf was setting up the Community Development Authority (CDA) for the Executive Council, Government of Dubai. He was responsible for the successful completion of the implementation of its first stage, delivering one of the components and social objectives of the Dubai strategic plan announced by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice-President and Prime Minister of UAE, Ruler of Dubai, in June 2007 to ensure the sustainable future development of Dubai.
Henry M. Kronenberg is Chief of the Endocrine Division at the Massachusetts General Hospital and Professor of Medicine at the Harvard Medical School. There he leads a research group that studies the actions of parathyroid hormone and parathyroid hormone-related protein, with a particular emphasis on bone development, the osteoblast lineage, calcium homeostasis, and the roles of osteoblast lineage cells in hematopoiesis.
Dr. Kronenberg received his BA from Harvard University, his MD from Columbia University, his medical house officer training at the Massachusetts General Hospital, and post-doctoral training at NIH, MIT, and the MGH.
Dr. Kronenberg is President of the Endocrine Society has served as President of the American Society for Bone and Mineral Research and of the International Bone and Mineral Society. He has won the Fuller Albright Young Investigator Award, the William F. Neuman Award, and the Rodan Mentoring Award of the American Society for Bone and Mineral Research.
Dr. Ian Blumer is an endocrinologist in Toronto, Canada. He is a director of the Charles H. Best Diabetes Centre and is a lecturer at the University of Toronto. Dr. Blumer is Chair of the Endocrine Society Diabetes and Pregnancy Clinical Practice Guideline task force, and is a faculty member of Taking Control of Your Diabetes.
Dr. Blumer has been awarded the Canadian Diabetes Association's highest clinical honour; the Gerald S. Wong Award, given in recognition of outstanding service and contribution to people living with diabetes. He has also been a nominee for both the American Diabetes Association Educator of the Year award and the American Diabetes Association Outstanding Physician-Clinician award.
Dr. Blumer is the author of 9 books including works on diabetes, prescription drug therapy, doctor-patient relationships, and, published under the pen name of Sidney Gale, has written the novel Unto the Breach. His books have been translated into French and Chinese.
Dr. Bantle is Professor of Medicine and Director of the Division of Endocrinology and Diabetes at the University of Minnesota. His research interests focus on the treatment of diabetes mellitus. He is/was Principal Investigator in the Diabetes Control and Complications Trial (DCCT) at the University of Minnesota, the Epidemiology of Diabetes Interventions and Complications (EDIC) at the University of Minnesota, and the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) at the University of Minnesota. Dr. Bantle has a long-standing interest in diabetes and nutrition and has evaluated the effects of dietary carbohydrates on glycemia and lipemia in diabetic subjects. In 2002 and 2006, he co-chaired the American Diabetes Association panel that developed nutrition recommendations for people with diabetes. More recently, his focus has shifted to methods to accomplish weight loss as primary treatment for overweight and obese subjects with type 2 diabetes. Recent studies have assessed low calorie diets, meal replacements and pharmacologic treatment for weight loss in subjects with type 2 diabetes. Dr. Bantle is also Co-principal Investigator of Study of Health Outcomes of Weight Loss (Look AHEAD) at the University of Minnesota. This study will assess long-term effects of weight loss on cardiovascular events and diabetes complications in overweight and obese patients with type 2 diabetes.
Dr. John P. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach.
Dr. Bilezikian belongs to a number of professional societies including the American Society for Bone and Mineral Research, of which he served as President, 1995-1996 and the International Society of Clinical Densitometry, of which he served as President, 1999-2001. He is a member of the Endocrine Society, the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the American College of Endocrinology that has designated him Master. He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004). He is Senior Associate Editor of the Journal of Bone and Mineral
Research (2008- ). His books include Editor-in-Chief of theParathyroids (1994, 2001), and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), and Principles of Bone Biology (1996, 2002, 2008) and Osteoporosis in Men (2010).
Laurence Katznelson, MD received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is a Professor of Neurosurgery and Medicine at Stanford University School of Medicine. At Stanford University, he is the Associate Dean of Graduate Medical Education and the Chair of the GME Committee. Dr. Katznelson is currently the Medical Director of the Pituitary Center at Stanford Hospital and Clinics. In the Endocrine Society, Dr. Katznelson has served as Chair of the Special Programs Committee and member of the Scientific and Educational Programs Core Committee and Publications Committee. He has served as Chair of the Task Forces for writing clinical guidelines for the approach to acromegaly for both The Endocrine Society and the American Association of Clinical Endocrinologists. In endocrinology, Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.
Michael S. Irwig, MD, F.A.C.E., is board-certified in Endocrinology & Metabolism and is an associate professor of Medicine at The George Washington University School of Medicine & Health Sciences.
Dr. Irwig is a general endocrinologist with a particular interest and expertise in androgens. His research has focused on men with persistent sexual and non-sexual side effects of finasteride (Propecia), the transgender community and men with borderline testosterone levels. He is a well-published author with his research appearing in multiple journals including Current Opinion in Endocrinology, Diabetes and Obesity, Diabetic Medicine, Endocrine Practice, JAMA Dermatology, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Psychiatry, Journal of Sexual Medicine, Lancet Diabetes & Endocrinology and Nature Reviews Urology. His research findings have been featured in many national and international mainstream publications and broadcast outlets including: The Today Show, NBC Nightly News, ABC World News, CBS News, MSNBC.com, CNN, Men's Health Magazine, Men's Journal and The Philadelphia Inquirer.
Dr. Irwig has presented over 75 lectures at hospitals and medical schools across the world on several topics including male hypogonadism, care of transgender patients and the use and abuse of anabolic steroids. He also serves as a reviewer for over 25 peer-reviewed medical journals.
He is currently is President of the mid-Atlantic chapter of the American Association of Clinical Endocrinologists (AACE). He serves on national committees for AACE as well as the Endocrine Society, including the Endocrine Self-Assessment Committee (ESAP).
Dr. Irwig received his M.D. degree from Cornell University and completed his residency in internal medicine at the University of Virginia. He was a senior fellow in endocrinology, metabolism, and nutrition at the University of Washington in Seattle.
Dr.Hassanein is a senior consultant in Endocrinology and Diabetes at Dubai Hospital, Dubai, UAE since 2014. He holds an Academic post of Senior Lecturer, and Associate Director for Postgraduate Diabetes Education, Cardiff University. UK since 2007. Dr Hassanein is the Chair of the scientific committee of the Arab Association for the Study of Diabetes and founding member in the Arab Diabetes Consensus Group. He is also Royal College of Physician's examiner for the PACES section of the exam. As part of a higher degree program with the Human Nutrition Unit of Reading University in conjunction with the Diabetes Centre of the Royal Berkshire Hospital. Dr Hassanein conducted five important clinical trials. Three of these trials are to assess the effect of zinc and chromium supplementation to the glycaemic control, lipids profile and manifestations of the metabolic syndrome of people with type 2 diabetes. Dr Hassanein has been principle and co-investigator in several landmark clinical trials and have number of publications related to the field of Diabetes.
Dr. Nabil is the Head of Department of Family and Community Medicine and Behavioural Sciences, senior consultant, the University of Sharjah, a senior Fellow at the Department of General Practice, The University of Melbourne, Australia, and a senior research fellow at the Baker/ International Heart and Diabetes Research Institute, Melbourne, Australia. Dr. Nabil has worked with distinction in several universities including Australia, the UK, Yemen and Iraq as well as Sharjah, winning several research and education awards. He is the principle investigator of several qualitative and quantitative diabetes and asthma research projects in Sharjah, UAE and Melbourne, Australia, including two NHMRC grants one on diabetes (the PEACH study: Patients Engagement and Coaching for Health) and the other on the effectiveness of spirometry in General Practice Asthma Care. Nabil has attended over thirty international/national conferences as speaker/ invited speaker. Most recently he was invited with colleagues from WHO centre from Pittsburgh University as speaker and facilitator for the ?Diabetes and NCD Super course? at Alexandria Library January 2009. Nabil has published in distinguished Journals including the British Medical J and Medical J of Australia. Most recently in Sep 2011 Nabil was invited byINSEAD University- France and Rutgers University to speak at their ?Global Thought Leadership Initiative on Global Health in Fontainebleau- France
Professor Peter Trainer qualified in Edinburgh and continued with his higher training in London (St Bartholomew's hospital); Aberdeen; Utrecht, Holland; and Portland, Oregon, USA. He was a senior lecturer at Barts before becoming a consultant endocrinologist at the Christie Hospital in 1998. Professor Trainer is an active leader in the medical community. He has served on the senior executive committees of the Society for Endocrinology (UK), the American Endocrine Society and the European Society for Endocrinology. He chaired the programme organising committee for the European Congress of Endocrinology (2011) and the clinical programme of the American Endocrine congress in 2007. Professor Trainer has published extensively, with over 150 papers in peer-reviewed journals. He is also a sought after lecturer and teacher, Chair of the European Society for Endocrinology education committee, and he has served on the editorial boards of The Journal of Clinical Endocrinology and Metabolism, Clinical Endocrinology, Treatments in Endocrinology, and GH and IGF Research. His prime areas of research are diseases of the pituitary and adrenal glands, particularly Cushing's syndrome and acromegaly.
Dr. Roger Chen is Director of Diabetes Services and Senior Staff Specialist in the Department of Endocrinology and Metabolism in Concord Hospital with clinical interests in general endocrinology, osteoporosis and diabetes. He is Clinical Associate Professor in Medicine at the University of Sydney and Adjunct Professor at the University of Technology, Sydney.
Dr. Chen is Endocrinologist at the Concord Centre for Cardiometabolic Health in Psychosis, an integrated multidisciplinary endocrine-psychiatry clinical and research centre. He has also established a multidisciplinary diabetes service at Concord Hospital incorporating exercise and psychological intervention and has research interests in diabetes prevention and mental illness. He is also one of the co-chairs of the New South Wales Government ACI Committee on Diabetes and Mental Health. He is the Australian Diabetes Society and Diabetes Australia representative in committees on mental health and diabetes. He particularly enjoys teaching at undergraduate and postgraduate levels both in Australia and beyond.
Dr. Ehtisham graduated from the University of Cambridge in the UK and conducted her clinical training at Addenbrooke's Hospital. She is an exceptionally experienced paediatric endocrinologist who has received many research awards for her investigations into childhood diabetes.
Prior to joining Mediclinic City Hospital, she was clinical lead for diabetes at the Royal Manchester Children's Hospital and she was also an honorary lecturer in Endocrinology at the University of Manchester.
Dr. Ehtisham received her CCST in Paediatric Endocrinology in 2007. She was also a member of the Royal College of Physicians Working Party on Obesity which published its report in 2013 and is part of the All Party Parliamentary Group on Obesity which meets regularly at the House of Commons in the UK.
Stephanie L. Lee, Ph.D., M.D., F.A.C.E., E.C.N.U graduated from UC San Diego with a MD and PhD in Physiology and Pharmacology and completed a molecular and clinical fellowship in Endocrinology. She is an Associate Professor of Medicine at the Boston University School of Medicine and Director of the Multidisciplinary Thyroid Health Center and the Thyroid Nodule and Cancer Research Center in the Section of Endocrinology, Diabetes and Nutrition at the Boston Medical Center. Dr. Lee has clinical expertise in the evaluation and management of thyroid disease and participated on the 2006 and 2009 American Thyroid Association evidence-based guidelines for the diagnosis and management of thyroid nodules and cancer. Her research interests are to improve the methods to diagnosis and manage thyroid cancer. Currently funded studies includes a large comprehensive multi-institution thyroid cancer registry and a prospective clinical trial using quantitative ultrasound for the evaluation of thyroid nodules.
Subodh Verma is a cardiac surgeon-scientist at St. Michael's Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis. He has been on the India Abroad Power List, recognized as one of Canada's Top 40 under 40, and honoured with the Howard Morgan Award from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is a member of the Royal Society of Canada College of New Scholars, Artists and Scientists, and an inductee of the American Association of Thoracic Surgeons. Dr.Verma runs a practice that encompasses the entire spectrum of adult cardiac surgery (with a special interest in mitral valve repair and bicuspid aortopathy).
He is involved in several clinical trials and oversees a dynamic pre-clinical research laboratory that focuses on the roles of risk factors, inflammation and autophagy in cardiovascular health. His innovative research has culminated in nearly 300 peer-reviewed papers and two United States patents. Dr.Verma's meta-analysis revealing that bypass surgery is superior to angioplasty in patients with diabetes has been used by the American College of Cardiology and the Canadian Cardiovascular Society (CCS) to shape the recommendations around the best clinical choice for revascularization procedures involving individuals with diabetes. He has contributed to the CCS guidelines for antiplatelet therapy, atrial fibrillation, dyslipidemia, peripheral arterial disease, and stable coronary artery disease; Canadian Cardiovascular Surgery Position Statement and Canadian Cardiometabolic Risk Position Paper. Dr.Verma spearheads the CARDIOLINK platform that will conduct clinical trials in atrial fibrillation, aneurysm and cerebral protection, diabetes and secondary prevention, valvular heart disease, and critical limb ischemia. He (co-)founded and (co-)chairs many regional and national educational initiatives that include the Landmark Lecture, State of the Heart Symposium, Toronto Acute Coronary Syndrome Summit, St. Michael's Heart Valve Summit, Advances in Cardiology, Current Issues in Cardiology, and At the Heart of Diabetes programs.
Steve Bain is the Clinical Director of the Diabetes Research Unit Cymru, and Assistant Medical Director for Research & Development for Abertawe Bro Morgannwg (ABM) University Health Board.
Professor Bain completed his undergraduate training at St John's College, Cambridge, and then was clinically trained at King's College Hospital, London. On qualifying in 1983, he went on to hold junior appointments in London, the East Midlands, and the West Midlands, UK. His research centred on the genetics of type 1 diabetes, and he was granted a Medical Research Council Lectureship. In 1993, he became a Senior Lecturer/Honorary Consultant Physician at Birmingham Heartlands Hospital, Birmingham, with promotion to Reader in Diabetic Medicine in 1998. Professor Bain became a Fellow of the Royal College of Physicians UK in 1996. Professor Bain was appointed to a newly created Chair in Medicine (Diabetes) in the University of Wales Swansea in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Principal Investigator for several multi-centre trials investigating novel therapies for diabetes.
Professor Bain is the Diabetes Lead Clinician for the ABM University Health Board and a member of the Wales Diabetes & Endocrine Society (WEDS) executive committee. He chairs the Joint Clinical Research Facility in Swansea and was Clinical Director of the Academic Health Science Collaboration (AHSC) in Wales until September 2015. He chaired the Diabetes & Endocrinology Specialist Training Committee (STC) for Wales 2010-2016 and is currently the chair of the National Specialist Advisory Group (NSAG) for Diabetes in Wales.
Padma Shri Dr. V. Mohan is an eminent Indian Diabetologist who has been working in the field of diabetes for over 30 years in Chennai in southern India. Dr. Mohan is the Chairman and Chief of Diabetology at Dr. Mohan's Diabetes Specialities Centre, a WHO Collaborating Centre for Noncommunicable Diseases Prevention and Control and an IDF Centre of Education. He is also President and Director of the Madras Diabetes Research Foundation.
Dr. Mohan completed his undergraduate (MBBS) and postgraduate medical education (MD, General Medicine) from Madras Medical College, Chennai, India. He then worked for a year as a Wellcome Trust Research Fellow at the Royal Postgraduate Medical School and Hammersmith Hospital, London, U.K and later for a year as an Alexander Von Humboldt Fellow at the University of Ulm, West Germany. He was awarded a Ph.D. and later a Doctor of Science (D.Sc.) for his research on diabetes.
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.
|MCI Middle East |
United Arab Emirates
Tel: +971 4 311 6300
Fax: +971 4 311 6301